33 employees
Synaffix BV creates an antibody conjugation technology platform to aid in the treatment of cancer and other disorders.
2014
Synaffix BV raised undisclosed on February 18, 2014
Investors: BOM (Brabantse Ontwikkelings Maatschappij), Aravis, BGV (BioGeneration Ventures) and M Ventures